Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 0.62 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.62 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15517438 | 0.89 | GRN (0.64) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL15517667 | 0.87 | GRN (0.46) | GRNSORT1KLKB1MAPK14CARM1 | |
| SCHEMBL1646829 | 0.78 | GRN (1.00) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL15517497 | 0.78 | GRN (0.46) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL2787544 | 0.77 | GRN (0.76) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL16749343 | 0.77 | GRN (0.76) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL15517113 | 0.77 | GRN (0.60) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL15517112 | 0.76 | GRN (0.59) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL16931583 | 0.76 | GRN (0.59) | GRNSORT1KLKB1MAPK14MAPK13 | |
| SCHEMBL2314764 | 0.76 | GRN (0.74) | GRNSORT1KLKB1MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796742-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| EP-2890460-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-02-22 | — | — | EP | disclosed |
| US-20160340375-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20150210722-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| EP-2890460-A1 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014033446-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210722-A1 | KINASE INHIBITORS | SYK, SRC, LYN | GRN 3360/4885SORT1 3500/4885KLKB1 2074/4885 |
| US-20160340375-A1 | KINASE INHIBITORS | SYK, LYN, BTK | GRN 3218/4885SORT1 3481/4885KLKB1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.